Urinary and plasma organic acids and amino acids in chronic fatigue syndrome.
Jones, Mark G, Cooper, Elizabeth, Amjad, Saira et al. · Clinica chimica acta; international journal of clinical chemistry · 2005 · DOI
Quick Summary
Researchers tested blood and urine samples from ME/CFS patients and compared them to healthy people, those with depression, and those with rheumatoid arthritis. Previous studies claimed certain chemicals in urine were markers for ME/CFS, but this study could not confirm those earlier findings. However, the study did find some signs of inflammation and possible muscle changes that might explain why ME/CFS patients experience fatigue and muscle pain.
Why It Matters
This study is important because it rigorously tests long-standing claims about specific metabolic markers in ME/CFS using better analytical methods, helping clarify which earlier findings are reproducible. The proposed inflammatory and muscular mechanisms offer a potential biological explanation for the fatigue and muscle pain that disable many ME/CFS patients. Understanding true biomarkers could eventually aid diagnosis and guide treatment development.
Observed Findings
Previously reported abnormalities in urinary amino acids and organic acids could not be confirmed in this patient cohort.
Evidence of underlying inflammatory disease was found in ME/CFS patients.
Indicators of reduced intramuscular collagen were observed in ME/CFS patients.
ME/CFS patients showed a lowered threshold for muscle micro-injury compared to controls.
Methodological problems in prior research limited the reliability of earlier metabolite findings.
Inferred Conclusions
Inflammation and muscle vulnerability, combined, may provide a biological basis for fatigue and muscle pain in ME/CFS.
Previous claims of specific urinary metabolic markers for ME/CFS were not supported by more rigorous analytical methods.
Muscular and inflammatory abnormalities warrant further investigation as potential contributors to ME/CFS pathophysiology.
Remaining Questions
Do inflammatory markers and collagen changes play a causative role in ME/CFS, or are they secondary to other processes?
What specific inflammatory mediators or pathways are active in ME/CFS patients compared to controls?
What This Study Does Not Prove
This study does not prove that inflammation or collagen changes directly cause ME/CFS—it only shows associations in patient samples. It does not validate previously reported metabolic markers, suggesting those earlier findings may have been false positives due to analytical method problems. The study cannot determine whether these changes are primary disease causes or secondary consequences of ME/CFS.